share_log

Connect Biopharma Lead Candidate Aces Pivotal Atopic Dermatitis Trial In Chinese Patients

Connect Biopharma Lead Candidate Aces Pivotal Atopic Dermatitis Trial In Chinese Patients

康乃德生物主要候選藥物ACES關鍵特應性皮炎中國患者試驗
Benzinga Real-time News ·  2022/10/04 11:41
  • Connect Biopharma Holdings Limited (NASDAQ:CNTB) announced topline results for the primary analysis population of the pivotal trial of CBP-201, in patients with moderate-to-severe atopic dermatitis (AD) in China.
  • This trial evaluates the efficacy and safety of CBP-201 as well as the potential for an extended CBP-201 dosing interval during the maintenance phase of treatment.
  • The primary endpoint of IGA of 0 or 1 ("clear" or "almost clear") with at least 2 grades of reduction at Week 16 from baseline was significantly greater for the CBP-201 (300 mg every two weeks) group with 30.3% of patients showing improvement compared to 7.5% for the placebo group.
  • Related: Connect Biopharma's Candidate For Skin Disease-Associated Itch Shows Encouraging Safety Profile.
  • Significant improvement in pruritus with 35.0% of patients experiencing a reduction of 4 or greater on the Peak Pruritus-Numerical Rating Scale (PP-NRS) compared to 9.6% for placebo.
  • CBP-201 was generally well tolerated, with safety results comparable to placebo.
  • Price Action: CNTB shares are down 0.95% at $1.2975 on the last check Tuesday.
  • 康乃德生物控股有限公司美國納斯達克公司(CBP：CNTB)宣佈了中國中重度特應性皮炎(AD)患者中CBP-201關鍵試驗的主要分析人羣的TOPLINE結果。
  • 這項試驗評估了CBP-201的有效性和安全性，以及在治療的維持階段延長CBP-201劑量間隔的可能性。
  • 在第16周，免疫球蛋白A的主要終點為0或1(“清晰”或“幾乎清晰”)，較基線至少降低2級，CBP-201組(每兩週300毫克)的患者明顯更多，30.3%的患者有改善，而安慰劑組為7.5%。
  • 相關： 康乃德生物治療皮膚病相關瘙癢的候選藥物顯示出令人鼓舞的安全性.
  • 瘙癢症狀顯著改善，35.0%的患者在峯值瘙癢-數字評定量表(PP-NRS)上減少了4次或更多，而服用安慰劑的患者只有9.6%。
  • CBP-201總體耐受性良好，安全性結果與安慰劑相當。
  • 價格行動：招商銀行股價週二尾盤下跌0.95%，至1.2975美元。
声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論